Abstract
Treatment for osteosarcoma is problematic because there are no prognostic markers. Diagnosis is primarily limited to cytologic grading. Oncogenesis alters cell structure therefore osteoblast tissue matrix proteins (extracellular matrix, cytoskeletal, intermediate filament, and nuclear matrix proteins), components of the cell substructure, are candidates for osteosarcoma markers. Structural proteins of the extracellular matrix, e.g. the collagens, are useful for diagnosis but not for tumors that produce little osteoid. To identify principal cellular tissue matrix proteins that distinguish normal from transformed human osteoblasts, their expression in normal osteoblasts, two osteosarcoma cell lines, and three primary osteosarcoma tumors were compared. The tumors were graded as (i) intermediate, (ii) high, and (iii) high grade recurrent. The 1-D SDS/PAGE profiles of the major components of the nuclear matrix and intermediate filament fractions from normal osteoblasts did not vary with biopsy site, age, or sex of patients. These profiles included known cytoskeletal proteins and OB250, a ∼250 kD protein(s) observed in the intermediate filament fraction. A loss of protein bands, including OB250, was observed in the osteosarcoma cell lines and tumors. The intermediate and high grade tumors exhibited nearly identical protein profiles including potential tumor-specific proteins and collagen, consistent with the presence of intracellular collagen fibers in osteosarcoma. A microsequence was obtained for OT25, a novel low molecular weight protein observed in osteosarcoma cell lines. Fibrinogen γ-chain, a protein that mediates cell adhesion was recovered from the high grade recurrent tumor.
Similar content being viewed by others
References
Huvos AG (1991) Bone tumors. Diagnosis, treatment, and prognosis. 2nd Edition.W.B. Saunders Company, Philadelphia PA
Dorfman HD & Czerniak B (1995) Cancer (Supplement) 75: 203–210
Mankin HJ, Gebhardt MC, Springfield DS, Litwak GJ, Kusazaki K & Rosenberg AE (1990) Clinical Orthopaedics and Related Research 270: 169–180
Rougraff BT, Simon MA, Kneisl JS, Greenberg DB & Mankin HJ (1994) J of Bone Joint Surg. 76: 649–656
Holme TC (1990) Eur. J. Sur. Oncol. 16: 161–169
Pienta KJ, Partin AW & Coffey DS (1989) Cancer Res. 49: 2555–2565
Folkman JW & Moscona A (1978) Nature 278: 345
Getzenberg RH, Pienta KJ & Coffey DS (1990) Endocrine Reviews 11: 399–417
Fey EG, Wan J & Penman S (1984) J. Cell Biol. 19: 1973–1984
Nickerson JA & Penman S (1992) Cell Biol. Int. Reports 16: 811–826
Berezney R (1991) J. Cell Biochem. 47: 109–123
Xing Y, Johnson CV, Dobner PR & Lawrence JB (1993) Science 259: 1326–1330
Bidwell JP, van Wijnen AJ, Fey EG, Dworetzky S, Penman S, Stein JL, Lian JB & Stein GS (1993) Proc. Natl. Acad. Sci. USA 90: 3162–3166
Dworetzky Sl, Fey EG, Penman S, Lian JB, Stein JL & Stein GS (1990) Proc. Natl. Acad. Sci. USA 87: 4605–4609
PaSe vinderjit KS, Lehr JE, Soule HD, Gehani SK, Noto AC, Choudhury S, Chen R & Pienta KJ (1993) Cancer Res. 53: 3394-3398
Keesee SK, Meneghini MD, Szaro RP & Wu Y-J (1994) Proc. Natl. Acad. Sci. USA 91: 1913–1916
Bidwell JP, Fey EG, van Wijnen AJ, Penman S, Stein JL, Lian JBW & Stein GS (1994) Cancer Research 54: 28–32
Murphy BC, Pienta KJ & Coffey DS (1992) The Prostate 20: 29–41
Kilianska Z, Krajewska WM, Xie R, Klyszejko-Stefanowicz L & Chiu JF (1991) J. Cell Biochem. 45: 303–310
Pienta KJ & Lehr JE (1993) A common set of nuclear matrix proteins in prostate cancer cells. Prostate 23: 1–67
Grundmann E, Roessner A, Ueda Y, Schneider-Stock R & Radig K (1995) Anticancer Research 15: 1023–1033
Robey PG & Termine JD (1985) Calcif. Tissue Int. 37: 453–460
Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA & Struhl D (1987) Current protocols in molecular biology. John Wiley & Sons, Inc, New York
Harlow E & Lane D (1988) Antibodies: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
Kallajoki M & Osborn M (1994) Electrophoresis 15: 520–528
Moll R, Franke WW, Schiller, Geiger B & Krepler R (1982) Cell 31: 11–24
Kaufmann SH, Marby M, Jasti R & Shaper JH (1991) Cancer Research 51: 581–586
Ghadially FN, Thomas MJ, Jabi M & Rippstein P (1993) Ultrastructural Pathology 17: 161–168
Welsh RA & Meyer AT (1967) Arch. Pathol. 84: 354–362
Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, Sage EH & Zern MA (1995) Hepatology 21: 847–854
Kopp JB, Bianco P, Young MF, Termine JD & Robey PG (1992) Kidney International 41: 56–64
Dickinson LA & Kohwi-Shigematsu T (1995) Mol. Cell Biol. 15: 456–465
Cross HS, Bajna E, Bises G, Genser D, Kallay E, Potzi R, Wenzl E, Wrba F, Roka R & Peterlik M (1996) Anticancer Research 16: 2333–2337
Honn KV, Tang DG & Chen YQ (1992) Seminars in Thrombosis and Hemostasis 18: 392–415
Languino LR, Duperray, Jognic KJ, Fornaro M, Thornton GB & Altieri DC (1995) Proc. Natl. Acad. Sci. USA 92: 1505–1509
Mintz KP, Grzesik WJ, Midura RJ, Gehron Robey P, Termine JD & Fisher LW (1993) J. Bone Min. Res. 8: 985–994
Chiang HS, Yang R-S & Huang T-F (1995) British J. Cancer 71: 265–270
Lee SY, Lee KP & Lim JW (1996) Thrombosis and Haemostasis 75: 466–470
Miller TE, Beausang LA, Winchell LF & Lidgard GP (1992) Cancer Res. 52: 422–427
Giaccone G (1994) Path. Biol. 42: 346–352
Dolye LA (1994) Cancer Chemotherapy Pharmacology 34(Suppl): S32–40
Compton DA & Luo C (1995) J. Cell Science 108: 621–633
Sparks CA, Fey EG, Vidair CA & Doxsey SJ (????) J Cell Science 108 (Pt 11): 3389-3396
Janmey PA & Chaponnier C (1995) Current Opinion in Cell Biology 7: 111–117
Ueda Y & Nakanishi I (1989) Virchows Archiv (B) 58: 79–88
Rights and permissions
About this article
Cite this article
Bidwell, J., McCabe, R., Rougraff, B. et al. Tissue matrix protein expression in human osteoblasts, osteosarcoma tumors, and osteosarcoma cell lines. Mol Biol Rep 24, 271–282 (1997). https://doi.org/10.1023/A:1006883528518
Issue Date:
DOI: https://doi.org/10.1023/A:1006883528518